Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Terragna

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Bone Marrow Transplantation|April 4, 2000
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapyG Martinelli, N Testoni, M Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myelomaG Martinelli, C Terragna, E Zamagni, et al.
British Journal of Haematology|December 3, 1999
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot studyR M Lemoli, G Martinelli, A Olivieri, et al.
Haematologica|September 12, 2000
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantationG Martinelli, C Terragna, E Zamagni, et al.
Leukemia|April 15, 2016
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosisM Martello, D Remondini, E Borsi, et al.
Blood Cancer Journal|January 27, 2022
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myelomaM Martello, A Poletti, E Borsi, et al.
Haematologica|March 20, 2001
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemiaM Amabile, B Giannini, N Testoni, et al.
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Bone Marrow Transplantation|April 4, 2000
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapyG Martinelli, N Testoni, M Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myelomaG Martinelli, C Terragna, E Zamagni, et al.
British Journal of Haematology|December 3, 1999
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot studyR M Lemoli, G Martinelli, A Olivieri, et al.
Haematologica|September 12, 2000
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantationG Martinelli, C Terragna, E Zamagni, et al.
Leukemia|April 15, 2016
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosisM Martello, D Remondini, E Borsi, et al.
Blood Cancer Journal|January 27, 2022
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myelomaM Martello, A Poletti, E Borsi, et al.
Haematologica|March 20, 2001
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemiaM Amabile, B Giannini, N Testoni, et al.
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Pageof 3